EXPAREL Data Links Reduced Opioid Use to Lower Healthcare Costs for Hip Arthroplasty Patients
Event summary
- A retrospective study analyzing Medicare patient data found EXPAREL® associated with significant reductions in opioid use (up to 637 MMEs at 90 days) following total hip arthroplasty.
- Patients receiving EXPAREL experienced lower healthcare utilization, including fewer inpatient admissions (42 vs 79 at 30 days) and emergency department visits (673 vs 639 at 30 days).
- Total medical costs were significantly lower for EXPAREL patients compared to those receiving standard care (e.g., $1233 vs $1627 at 30 days).
- The data was presented at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting on April 16-18, 2026.
- The study analyzed data up to 365 days post-surgery, demonstrating sustained reductions in opioid use and healthcare costs.
The big picture
Pacira's EXPAREL is positioned to benefit from the ongoing push to reduce opioid dependence in surgical settings, particularly among vulnerable Medicare populations. The study’s findings on reduced healthcare costs provide a compelling economic argument for wider adoption, potentially displacing standard-of-care options and generating significant revenue for Pacira. However, the company faces ongoing pressure to demonstrate long-term clinical efficacy and manage potential pricing headwinds from payers.
What we're watching
- Market Adoption
- The pace at which EXPAREL adoption expands within the broader orthopedic surgery market will depend on reimbursement policies and physician education regarding its benefits.
- Competitive Dynamics
- How competitors respond to EXPAREL’s demonstrated cost savings and reduced opioid usage will shape the long-term market landscape for regional anesthesia.
- Regulatory Scrutiny
- Increased scrutiny from CMS and other payers regarding opioid usage and associated healthcare costs could accelerate EXPAREL adoption, but also introduce pricing pressures.
Related topics